APLS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $14,603,529.38

Apellis Pharmaceuticals Insider Trading History Chart

Apellis Pharmaceuticals Share Price & Price History

^$17.21

▼ -0.76 (-4.23%)

As of 03/20/2026 05:00 PM ET

Days: 30 | 90 | 365

Apellis Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/11/2026	Mark Jeffrey DeLong	Insider	Sell	368	$22.15	$8,151.20	114,591
1/22/2026	Caroline Baumal	Insider	Sell	2,797	$21.77	$60,890.69	86,527
1/22/2026	Cedric Francois	CEO	Sell	27,192	$21.77	$591,969.84	286,045
1/22/2026	David O. Watson	General Counsel	Sell	7,832	$21.77	$170,502.64	88,531
1/22/2026	James George Chopas	CAO	Sell	2,064	$21.77	$44,933.28	49,805
1/22/2026	Mark Jeffrey DeLong	Insider	Sell	3,371	$21.77	$73,386.67	78,353
1/22/2026	Nur Nicholson	Insider	Sell	7,725	$21.77	$168,173.25	71,118
1/22/2026	Pascal Deschatelets	Insider	Sell	5,928	$21.77	$129,052.56	1,151,382
1/22/2026	Timothy Eugene Sullivan	CFO	Sell	10,287	$21.77	$223,947.99	93,901
1/20/2026	Caroline Baumal	Insider	Sell	1,882	$19.79	$37,244.78	89,324
1/20/2026	Cedric Francois	CEO	Sell	8,182	$19.79	$161,921.78	313,237
1/20/2026	David O. Watson	General Counsel	Sell	2,475	$19.79	$48,980.25	96,363
1/20/2026	James George Chopas	CAO	Sell	726	$19.79	$14,367.54	51,869
1/20/2026	Mark Jeffrey DeLong	Insider	Sell	1,334	$19.79	$26,399.86	81,724
1/20/2026	Nur Nicholson	Insider	Sell	2,203	$19.79	$43,597.37	78,843
1/20/2026	Pascal Deschatelets	Insider	Sell	909	$19.79	$17,989.11	1,157,310
1/20/2026	Timothy Eugene Sullivan	CFO	Sell	2,892	$19.79	$57,232.68	104,188
1/13/2026	Cedric Francois	CEO	Sell	10,186	$22.19	$226,027.34	321,419
1/13/2026	David O. Watson	General Counsel	Sell	5,780	$22.19	$128,258.20	98,838
1/13/2026	James George Chopas	CAO	Sell	873	$22.19	$19,371.87	52,595
1/13/2026	Mark Jeffrey DeLong	Insider	Sell	1,780	$22.19	$39,498.20	83,058
1/13/2026	Nur Nicholson	Insider	Sell	2,618	$22.19	$58,093.42	81,046
1/13/2026	Pascal Deschatelets	Insider	Sell	2,277	$22.19	$50,526.63	1,158,219
1/13/2026	Timothy Eugene Sullivan	CFO	Sell	3,856	$22.19	$85,564.64	107,080
12/16/2025	David O. Watson	General Counsel	Sell	5,000	$24.49	$122,450.00	103,730
11/17/2025	David O. Watson	General Counsel	Sell	5,000	$20.06	$100,300.00	108,730
10/21/2025	Timothy Eugene Sullivan	CFO	Sell	10,000	$28.03	$280,300.00	110,936
10/16/2025	David O. Watson	General Counsel	Sell	5,000	$25.22	$126,100.00	113,730
10/10/2025	A. Sinclair Dunlop	Director	Sell	31,092	$23.72	$737,502.24	3,837
9/19/2025	A. Sinclair Dunlop	Director	Sell	31,092	$22.95	$713,561.40	68,908
9/16/2025	David O. Watson	General Counsel	Sell	5,000	$24.34	$121,700.00	118,730
9/15/2025	James George Chopas	CAO	Sell	189	$24.19	$4,571.91	53,468
9/2/2025	James George Chopas	CAO	Sell	548	$28.08	$15,387.84	53,657
8/28/2025	Cedric Francois	CEO	Sell	49,963	$28.39	$1,418,449.57	307,946
8/27/2025	Cedric Francois	CEO	Sell	175,037	$28.19	$4,934,293.03	357,909
8/18/2025	David O. Watson	General Counsel	Sell	5,000	$27.80	$139,000.00	123,730
7/17/2025	Cedric Francois	CEO	Sell	19,725	$20.21	$398,642.25	331,605
7/16/2025	David O. Watson	General Counsel	Sell	5,000	$19.55	$97,750.00	128,730
7/15/2025	Cedric Francois	CEO	Sell	1,900	$20.09	$38,171.00	342,333
7/14/2025	Cedric Francois	CEO	Sell	137,465	$20.19	$2,775,418.35	343,433
6/16/2025	David O. Watson	General Counsel	Sell	5,000	$18.77	$93,850.00	133,730
3/17/2025	James George Chopas	CAO	Sell	183	$24.82	$4,542.06	47,955
3/5/2025	David O. Watson	General Counsel	Sell	5,569	$25.10	$139,781.90	138,730
2/11/2025	Mark Jeffrey DeLong	Insider	Sell	363	$28.54	$10,360.02	83,945
1/29/2025	Cedric Francois	CEO	Sell	2,824	$29.52	$83,364.48	415,695
1/29/2025	David O. Watson	General Counsel	Sell	695	$29.52	$20,516.40	144,299
1/29/2025	Nur Nicholson	Insider	Sell	825	$29.52	$24,354.00	83,664
1/29/2025	Timothy Eugene Sullivan	CFO	Sell	546	$29.52	$16,117.92	128,665
1/22/2025	Cedric Francois	CEO	Sell	13,551	$30.43	$412,356.93	418,519
1/22/2025	David O. Watson	General Counsel	Sell	3,323	$30.43	$101,118.89	144,994
1/22/2025	James George Chopas	CAO	Sell	1,096	$30.43	$33,351.28	48,138
1/22/2025	Nur Nicholson	Insider	Sell	3,948	$30.43	$120,137.64	84,489
1/22/2025	Timothy Eugene Sullivan	CFO	Sell	3,088	$30.43	$93,967.84	129,211
1/17/2025	Cedric Francois	CEO	Sell	6,007	$29.96	$179,969.72	301,408
1/17/2025	David O. Watson	General Counsel	Sell	2,201	$29.96	$65,941.96	105,555
1/17/2025	James George Chopas	CAO	Sell	715	$29.96	$21,421.40	36,643
1/17/2025	Nur Nicholson	Insider	Sell	2,145	$29.96	$64,264.20	52,011
1/17/2025	Timothy Eugene Sullivan	CFO	Sell	1,730	$29.96	$51,830.80	86,370
1/13/2025	Cedric Francois	CEO	Sell	6,247	$28.70	$179,288.90	307,415
1/13/2025	David O. Watson	General Counsel	Sell	4,965	$28.70	$142,495.50	107,756
1/13/2025	James George Chopas	CAO	Sell	783	$28.70	$22,472.10	37,358
1/13/2025	Jeffrey Eisele	Insider	Sell	264	$28.70	$7,576.80	56,881
1/13/2025	Timothy Eugene Sullivan	CFO	Sell	2,170	$28.70	$62,279.00	88,100
1/6/2025	Caroline Baumal	Insider	Sell	2,816	$33.81	$95,208.96	55,560
12/23/2024	Jeffrey Eisele	Insider	Sell	63	$33.09	$2,084.67	57,145
9/16/2024	A. Sinclair Dunlop	Director	Sell	37,000	$36.23	$1,340,510.00	100,000
6/21/2024	A. Sinclair Dunlop	Director	Sell	37,000	$39.24	$1,451,880.00	136,998
5/8/2024	Pascal Deschatelets	Insider	Sell	78,907	$42.35	$3,341,711.45	1,115,983
4/8/2024	Pascal Deschatelets	Insider	Sell	69,107	$54.17	$3,743,526.19	1,115,983
4/1/2024	Timothy Eugene Sullivan	CFO	Sell	4,000	$58.66	$234,640.00	93,338
3/19/2024	A. Sinclair Dunlop	Director	Sell	18,681	$57.18	$1,068,179.58	173,998
3/18/2024	Mark Jeffrey DeLong	Insider	Sell	9,913	$56.90	$564,049.70	54,693
3/15/2024	James George Chopas	CAO	Sell	184	$56.46	$10,388.64	38,883
3/13/2024	Nur Nicholson	Insider	Sell	11,220	$57.56	$645,823.20	56,287
3/1/2024	Cedric Francois	CEO	Sell	250,000	$64.11	$16,027,500.00	313,662
3/1/2024	Timothy Eugene Sullivan	CFO	Sell	6,000	$63.22	$379,320.00	93,338
2/12/2024	Adam J. Townsend	Insider	Sell	1,148	$67.77	$77,799.96	92,453
2/12/2024	Cedric Francois	CEO	Sell	3,962	$67.77	$268,504.74	313,662
2/12/2024	David O. Watson	General Counsel	Sell	781	$67.77	$52,928.37	103,390
2/12/2024	Timothy Eugene Sullivan	CFO	Sell	1,431	$67.77	$96,978.87	93,338
1/29/2024	Cedric Francois	CEO	Sell	2,843	$64.14	$182,350.02	317,624
1/29/2024	David O. Watson	General Counsel	Sell	906	$64.14	$58,110.84	104,171
1/29/2024	Nur Nicholson	Insider	Sell	835	$64.14	$53,556.90	67,507
1/22/2024	Adam J. Townsend	Insider	Sell	3,413	$65.00	$221,845.00	94,507
1/22/2024	Cedric Francois	CEO	Sell	13,431	$65.00	$873,015.00	320,467
1/22/2024	David O. Watson	General Counsel	Sell	4,184	$65.00	$271,960.00	105,077
1/22/2024	James George Chopas	CAO	Sell	1,061	$65.00	$68,965.00	39,067
1/22/2024	Timothy Eugene Sullivan	CFO	Sell	3,551	$65.00	$230,815.00	95,675
1/16/2024	Cedric Francois	CEO	Sell	7,851	$66.81	$524,525.31	333,898
1/16/2024	David O. Watson	General Counsel	Sell	4,240	$66.81	$283,274.40	109,261
1/16/2024	James George Chopas	CAO	Sell	864	$66.81	$57,723.84	40,128
1/16/2024	Jeffrey Eisele	Insider	Sell	438	$66.81	$29,262.78	72,650
1/16/2024	Timothy Eugene Sullivan	CFO	Sell	2,235	$66.81	$149,320.35	99,226
1/4/2024	Caroline Baumal	Insider	Sell	2,751	$60.05	$165,197.55	32,931
12/26/2023	Jeffrey Eisele	Insider	Sell	68	$57.86	$3,934.48	53,815
12/19/2023	David O. Watson	General Counsel	Sell	3,905	$57.23	$223,483.15	89,753
12/1/2023	Lukas Scheibler	Insider	Sell	10,000	$60.00	$600,000.00	68,299
11/21/2023	Cedric Francois	CEO	Sell	5,000	$48.80	$244,000.00	269,655
11/17/2023	Alec Machiels	Director	Sell	1,250	$47.74	$59,675.00	367,420
11/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$47.27	$567,240.00	1,071,807
10/23/2023	James George Chopas	CAO	Sell	132	$46.04	$6,077.28	32,680
10/23/2023	Mark Jeffrey DeLong	Insider	Sell	131	$46.04	$6,031.24	51,622
10/17/2023	Alec Machiels	Director	Sell	1,250	$48.50	$60,625.00	367,420
10/9/2023	Pascal Deschatelets	Insider	Sell	12,000	$40.38	$484,560.00	1,066,313
9/18/2023	Alec Machiels	Director	Sell	1,250	$45.00	$56,250.00	367,420
9/18/2023	Nur Nicholson	Insider	Sell	20,350	$44.27	$900,894.50	53,284
9/15/2023	Alec Machiels	Director	Sell	1,250	$45.34	$56,675.00	367,420
9/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$42.87	$514,440.00	1,059,813
9/1/2023	Cedric Francois	CEO	Sell	150,000	$41.75	$6,262,500.00	424,655
8/31/2023	James George Chopas	CAO	Sell	551	$41.23	$22,717.73	30,312
8/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$23.66	$283,920.00	1,053,313
7/17/2023	Alec Machiels	Director	Sell	1,250	$64.79	$80,987.50	267,641
7/10/2023	Pascal Deschatelets	Insider	Sell	12,000	$84.55	$1,014,600.00	1,046,813
7/3/2023	David O. Watson	General Counsel	Sell	8,510	$89.98	$765,729.80	85,753
7/3/2023	Timothy Eugene Sullivan	CFO	Sell	6,779	$89.97	$609,906.63	77,713
6/20/2023	Alec Machiels	Director	Sell	1,250	$88.41	$110,512.50	267,641
6/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$91.35	$1,096,200.00	1,040,313
6/5/2023	Timothy Eugene Sullivan	CFO	Sell	69,779	$88.80	$6,196,375.20	77,713
6/1/2023	Karen Lewis	Insider	Sell	5,000	$86.00	$430,000.00	41,504
5/17/2023	Alec Machiels	Director	Sell	1,250	$88.66	$110,825.00	267,641
5/16/2023	Cedric Francois	CEO	Sell	30,000	$85.66	$2,569,800.00	274,655
5/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$92.39	$1,108,680.00	1,033,813
5/3/2023	Adam J. Townsend	Insider	Sell	5,000	$82.71	$413,550.00	75,995
4/18/2023	Cedric Francois	CEO	Sell	30,000	$82.02	$2,460,600.00	637,601
4/17/2023	Alec Machiels	Director	Sell	1,250	$81.05	$101,312.50	267,641
4/10/2023	Pascal Deschatelets	Insider	Sell	12,000	$78.21	$938,520.00	1,027,313
4/3/2023	A. Sinclair Dunlop	Director	Sell	500	$74.05	$37,025.00	131,297
4/3/2023	Karen Lewis	Insider	Sell	5,000	$75.00	$375,000.00	41,430
3/21/2023	Cedric Francois	CEO	Sell	30,000	$62.74	$1,882,200.00	1,144,591
3/17/2023	Alec Machiels	Director	Sell	1,250	$64.03	$80,037.50	267,641

SEC Filings (Institutional Ownership Changes) for Apellis Pharmaceuticals (NASDAQ:APLS)

96.29% of Apellis Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Apellis Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/19/2026	T. Rowe Price Investment Management Inc.	1,974	$50K	0.0%	-96.0%	0.002%
2/19/2026	Invesco Ltd.	225,976	$5.68M	0.0%	+23.5%	0.179%
2/18/2026	Mercer Global Advisors Inc. ADV	17,668	$0.44M	0.0%	-54.7%	0.014%
2/18/2026	Vident Advisory LLC	15,553	$0.39M	0.0%	-56.0%	0.012%
2/18/2026	Mackenzie Financial Corp	96,211	$2.42M	0.0%	+25.4%	0.076%
2/18/2026	NewEdge Advisors LLC	14,570	$0.37M	0.0%	N/A	0.012%
2/18/2026	Voloridge Investment Management LLC	461,186	$11.59M	0.0%	-53.5%	0.365%
2/18/2026	Virtus Investment Advisers LLC	27,086	$0.68M	0.2%	+17.4%	0.021%
2/18/2026	Twinbeech Capital LP	13,152	$0.33M	0.0%	+47.3%	0.010%
2/18/2026	Sphera Funds Management LTD.	250,961	$6.30M	1.2%	+294.2%	0.198%
2/18/2026	Suvretta Capital Management LLC	4,139,426	$103.98M	2.1%	+43.8%	3.272%
2/18/2026	Quadrature Capital Ltd	24,075	$0.61M	0.0%	N/A	0.019%
2/18/2026	RTW Investments LP	7,666,764	$192.59M	1.9%	N/A	6.059%
2/18/2026	Orbimed Advisors LLC	2,429,868	$61.04M	1.3%	-5.6%	1.920%
2/18/2026	Odyssean LLC	19,207	$0.48M	0.3%	N/A	0.015%
2/18/2026	Millennium Management LLC	946,459	$23.78M	0.0%	-29.6%	0.748%
2/18/2026	Man Group plc	144,271	$3.62M	0.0%	+114.7%	0.114%
2/18/2026	Ishara Investments LP	50,000	$1.26M	1.5%	N/A	0.040%
2/18/2026	Janus Henderson Group PLC	230,320	$5.79M	0.0%	+569.3%	0.182%
2/18/2026	Gotham Asset Management LLC	168,455	$4.23M	0.0%	+32.5%	0.133%
2/18/2026	Elmind Capital LP	50,000	$1.26M	0.4%	N/A	0.040%
2/18/2026	Apis Capital Advisors LLC	192,000	$4.82M	0.8%	N/A	0.152%
2/18/2026	683 Capital Management LLC	330,000	$8.29M	0.4%	+14.6%	0.261%
2/17/2026	Freestone Grove Partners LP	12,537	$0.32M	0.0%	N/A	0.010%
2/17/2026	Guggenheim Capital LLC	36,647	$0.92M	0.0%	+8.3%	0.029%
2/17/2026	AQR Capital Management LLC	2,276,687	$57.19M	0.0%	-49.3%	1.799%
2/17/2026	Jain Global LLC	16,877	$0.42M	0.0%	N/A	0.013%
2/17/2026	Trexquant Investment LP	194,592	$4.89M	0.0%	-66.8%	0.154%
2/17/2026	Amundi	30,721	$0.77M	0.0%	-97.9%	0.024%
2/17/2026	Jump Financial LLC	193,876	$4.87M	0.1%	-30.2%	0.153%
2/17/2026	Price T Rowe Associates Inc. MD	95,035	$2.39M	0.0%	-3.0%	0.075%
2/17/2026	T. Rowe Price Investment Management Inc.	1,974	$50K	0.0%	-96.0%	0.002%
2/17/2026	Rock Springs Capital Management LP	150,500	$3.78M	0.2%	+63.6%	0.119%
2/17/2026	Quantitative Investment Management LLC	8,611	$0.22M	0.0%	N/A	0.007%
2/17/2026	Integral Health Asset Management LLC	200,000	$5.02M	0.2%	-20.0%	0.158%
2/17/2026	Public Employees Retirement System of Ohio	32,448	$0.82M	0.0%	-3.7%	0.026%
2/17/2026	State of Wisconsin Investment Board	66,916	$1.68M	0.0%	-22.0%	0.053%
2/17/2026	ExodusPoint Capital Management LP	171,156	$4.30M	0.0%	-12.1%	0.135%
2/17/2026	Royal Bank of Canada	88,687	$2.23M	0.0%	-39.3%	0.070%
2/17/2026	Graham Capital Management L.P.	9,302	$0.23M	0.0%	-59.9%	0.007%
2/17/2026	Polar Capital Holdings Plc	3,706,510	$93.11M	0.4%	+39.9%	2.929%
2/16/2026	Squarepoint Ops LLC	192,156	$4.83M	0.0%	+140.7%	0.152%
2/16/2026	Panagora Asset Management Inc.	42,134	$1.06M	0.0%	N/A	0.033%
2/16/2026	Maven Securities LTD	15,000	$0.38M	0.0%	N/A	0.012%
2/16/2026	Entropy Technologies LP	23,128	$0.58M	0.0%	-6.0%	0.018%
2/13/2026	Marshall Wace LLP	990,848	$24.89M	0.0%	+149.8%	0.783%
2/13/2026	CANADA LIFE ASSURANCE Co	8,495	$0.21M	0.0%	-52.1%	0.007%
2/13/2026	Bridgewater Associates LP	143,805	$3.61M	0.0%	N/A	0.114%
2/13/2026	Stifel Financial Corp	36,661	$0.92M	0.0%	N/A	0.029%
2/13/2026	Hudson Bay Capital Management LP	1,179,828	$29.64M	0.1%	+181.9%	0.932%
2/13/2026	Quarry LP	5,000	$0.13M	0.0%	-68.8%	0.004%
2/13/2026	Bridgefront Capital LLC	11,326	$0.29M	0.1%	N/A	0.009%
2/13/2026	Bank of Nova Scotia	1,070,141	$26.88M	0.0%	-26.5%	0.846%
2/13/2026	Exome Asset Management LLC	135,849	$3.41M	1.6%	N/A	0.107%
2/13/2026	Morgan Stanley	9,173,004	$230.43M	0.0%	-4.9%	7.250%
2/13/2026	Schroder Investment Management Group	329,134	$8.31M	0.0%	+90.2%	0.260%
2/13/2026	Rafferty Asset Management LLC	171,456	$4.31M	0.0%	+1.8%	0.136%
2/13/2026	First Trust Advisors LP	495,947	$12.46M	0.0%	N/A	0.392%
2/13/2026	Charles Schwab Investment Management Inc.	644,445	$16.19M	0.0%	-0.4%	0.509%
2/13/2026	Police & Firemen s Retirement System of New Jersey	46,009	$1.16M	0.0%	-4.9%	0.036%
2/13/2026	State Street Corp	4,613,446	$115.89M	0.0%	+14.3%	3.646%
2/13/2026	Ieq Capital LLC	25,500	$0.64M	0.0%	-91.4%	0.020%
2/13/2026	Vontobel Holding Ltd.	34,039	$0.86M	0.0%	N/A	0.027%
2/13/2026	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	178,888	$4.49M	0.0%	+6.8%	0.141%
2/13/2026	Wells Fargo & Company MN	103,815	$2.61M	0.0%	+4,115.0%	0.082%
2/13/2026	Rhenman & Partners Asset Management AB	374,450	$9.41M	0.9%	+61.2%	0.296%
2/12/2026	Laurel Oak Wealth Management LLC	8,465	$0.21M	0.0%	N/A	0.007%
2/12/2026	HRT Financial LP	192,488	$4.84M	0.0%	-45.6%	0.152%
2/12/2026	State Board of Administration of Florida Retirement System	96,125	$2.42M	0.0%	+0.6%	0.076%
2/12/2026	Renaissance Technologies LLC	633,058	$15.90M	0.0%	-12.4%	0.500%
2/12/2026	Dimensional Fund Advisors LP	180,925	$4.55M	0.0%	+868.0%	0.143%
2/12/2026	Ensign Peak Advisors Inc	4,747	$0.12M	0.0%	-71.3%	0.004%
2/12/2026	Marex Group plc	23,000	$0.58M	0.0%	N/A	0.018%
2/12/2026	Steward Partners Investment Advisory LLC	81,698	$2.05M	0.0%	-28.4%	0.065%
2/12/2026	New York State Common Retirement Fund	104,018	$2.61M	0.0%	+113.0%	0.082%
2/12/2026	Granite Investment Partners LLC	327,094	$8.22M	0.5%	N/A	0.259%
2/12/2026	Bank of Montreal Can	176,571	$4.44M	0.0%	+10.1%	0.140%
2/12/2026	Alps Advisors Inc.	103,696	$2.61M	0.0%	+65.1%	0.082%
2/12/2026	Swiss National Bank	149,500	$3.76M	0.0%	+2.3%	0.118%
2/12/2026	Nuveen LLC	681,819	$17.13M	0.0%	+2.5%	0.539%
2/12/2026	Xponance LLC	18,164	$0.46M	0.0%	+3.9%	0.014%
2/11/2026	Deutsche Bank AG	1,385,263	$34.80M	0.0%	-7.9%	1.095%
2/11/2026	Cerity Partners LLC	23,971	$0.60M	0.0%	-81.3%	0.019%
2/11/2026	Franklin Resources Inc.	11,304	$0.28M	0.0%	N/A	0.009%
2/11/2026	ING Groep NV	139,000	$3.49M	0.0%	-88.2%	0.110%
2/11/2026	Los Angeles Capital Management LLC	951,716	$23.91M	0.1%	+53.3%	0.752%
2/11/2026	WINTON GROUP Ltd	86,653	$2.18M	0.1%	N/A	0.068%
2/11/2026	Arrowpoint Investment Partners Singapore Pte. Ltd.	10,806	$0.27M	0.0%	N/A	0.009%
2/11/2026	Vise Technologies Inc.	9,012	$0.23M	0.0%	N/A	0.007%
2/10/2026	Goldman Sachs Group Inc.	189,205	$4.75M	0.0%	+52.1%	0.150%
2/10/2026	Dynasty Wealth Management LLC	9,227	$0.23M	0.0%	N/A	0.007%
2/10/2026	BNP Paribas Financial Markets	557,591	$14.01M	0.0%	-42.7%	0.441%
2/10/2026	Norges Bank	1,198,444	$30.11M	0.0%	N/A	0.947%
2/9/2026	Geode Capital Management LLC	2,025,669	$50.90M	0.0%	-2.3%	1.601%
2/9/2026	Simplify Asset Management Inc.	538,008	$13.52M	0.2%	+403.3%	0.425%
2/6/2026	EverSource Wealth Advisors LLC	2,602	$65K	0.0%	-46.5%	0.002%
2/6/2026	PSP Research LLC	21,866	$0.55M	0.5%	N/A	0.017%
2/6/2026	PNC Financial Services Group Inc.	53,526	$1.35M	0.0%	-1.0%	0.042%
2/6/2026	Handelsbanken Fonder AB	35,400	$0.89M	0.0%	-9.5%	0.028%
2/6/2026	Profund Advisors LLC	61,832	$1.55M	0.0%	+78.1%	0.049%

Data available starting January 2016

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $17.21

$17.16

$18.09

50 Day Range

MA: $21.14

$17.21

$23.49

52 Week Range

Now: $17.21

$16.10

$30.48

Volume

5,601,952 shs

Average Volume

2,195,757 shs

Market Capitalization

$2.20 billion

P/E Ratio

132.39

Dividend Yield

N/A

Beta

0.26

Who are the company insiders with the largest holdings of Apellis Pharmaceuticals?: Apellis Pharmaceuticals' top insider investors include:
Pascal Deschatelets (Insider)
Cedric Francois (CEO)
David O Watson (General Counsel)
A Sinclair Dunlop (Director)
Timothy Eugene Sullivan (CFO)
Mark Jeffrey Delong (Insider)
Caroline Baumal (Insider)
Nur Nicholson (Insider)
Jeffrey Eisele (Insider)
James George Chopas (CAO)
Learn More about top insider investors at Apellis Pharmaceuticals.
Who are the major institutional investors of Apellis Pharmaceuticals?: Apellis Pharmaceuticals' top institutional shareholders include:
Vanguard Group Inc. — 8.44%
Morgan Stanley — 7.25%
RTW Investments LP — 6.06%
State Street Corp — 3.65%
UBS Group AG — 3.31%
Suvretta Capital Management LLC — 3.27%
Learn More about top institutional investors of Apellis Pharmaceuticals stock.
Which institutional investors are selling Apellis Pharmaceuticals stock?: Within the last quarter, APLS stock was sold by these institutional investors:
Jennison Associates LLC
AQR Capital Management LLC
Amundi
ING Groep NV
Voloridge Investment Management LLC
Morgan Stanley
BNP Paribas Financial Markets
Millennium Management LLC
In the last year, company insiders that have sold Apellis Pharmaceuticals company stock include:
Pascal Deschatelets (Insider)
Cedric Francois (CEO)
David O Watson (General Counsel)
A Sinclair Dunlop (Director)
Timothy Eugene Sullivan (CFO)
Mark Jeffrey Delong (Insider)
Caroline Baumal (Insider)
Nur Nicholson (Insider)
Jeffrey Eisele (Insider)
Learn More investors selling Apellis Pharmaceuticals stock.
Which institutional investors are buying Apellis Pharmaceuticals stock?: During the previous quarter, APLS stock was purchased by institutional investors including:
RTW Investments LP
Suvretta Capital Management LLC
Norges Bank
Polar Capital Holdings Plc
Hudson Bay Capital Management LP
UBS Group AG
Vanguard Group Inc.
Marshall Wace LLP